The INCOGNITO research project trial is now fully recruited at our site. The last of 20 patients was randomised to the trial on the 21st June 2018.
Well done to Mo, Norma and the rest of our team for their hard work.
COPD patients are all different and there are now a number of different medications available. Some treatments that are of benefit to one group of patients may produce side effects in other patients.
The trial will compare two different inhalers that are both licensed for treatment of COPD. We believe that the two inhalers will have different effects on the bacteria that live in the lungs and on the inflammation in the lungs.
If we are right, it means that in future we could match the right inhaler to the right patient by measuring their levels of inflammation at the start, thereby reducing the risks of side effects and increasing the effectiveness of the treatment.